Project Grant R43AI167263

Award Date 4/15/22
Completion Date 3/31/24
Dollars Obligated $571K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Menlo Park, CA 94025, USA
Similar Awards
This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
This $960,000 National Science Foundation project grant supports the development of a multiplexed plasmon-enhanced lateral flow assay for point-of-care detection of SARS-CoV-2 RNA and antigens. Funded under the NSF Engineering program (CFDA 47.041), the grantee, Washington University, will design, validate and build a novel diagnostic platform with sensitivity exceeding standard laboratory tests. Key deliverables include an ultrasensitive multiplexed lateral flow assay for simultaneous...
Numentus Technologies Inc. received a $303,685 Project Grant award from the National Science Foundation on February 15, 2021 to develop rapid planar PCR technology for COVID-19 testing. The award was made under the NSF's Engineering program (CFDA 47.041) to support innovation and excellence in engineering research. Through this funding, Numentus will work to advance the development of planar PCR, a technology that enables highly sensitive COVID-19 detection on a single integrated testing...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $331,189 to develop a new, affordable technology for virus detection. The project integrates protein engineering and electrochemical biosensors to create a portable, room-temperature stable platform for virus testing in resource-limited environments. Key innovations include the use of stable enzymes that can be stored at ambient temperatures,...
This National Science Foundation Technology, Innovation, and Partnerships Project Grant totaling $265,999 will support Rutgers, The State University of New Jersey, Camden in developing a rapid and reliable point-of-care screening for infectious diseases such as COVID-19. Specifically, the university will demonstrate a mass screening method to rapidly detect viruses to identify early infected individuals for quarantine. This work will enable rapid and reliable point-of-care detection with...
This Project Grant award of $3,055,197.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and evaluation of a rapid, low-cost phenotypic test for the detection of carbapenemase-producing organisms (CPOs). The objective is to create a structurally-programmed sticker microfluidic test that can provide rapid, objective carbapenemase detection and distinguish between carbapenemase...
This $968,765 Project Grant awarded by the National Science Foundation's (NSF) Division of Mathematical Sciences (CFDA 47.049 - Mathematical and Physical Sciences) will develop a flexible modeling framework to simulate the impact of various testing-based infection control strategies for respiratory pathogens like SARS-CoV-2. The project aims to improve our ability to control existing respiratory diseases and enhance preparedness for future pandemics. Key deliverables include: Developing a...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Anvil Diagnostics Inc. in the amount of $298,646, aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples using digital PCR hardware. The proposed technology seeks to comprehensively identify and quantify a panel of 17 common sepsis-causing pathogens within 4 hours from small blood volumes,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
Controlpoint Inc. was awarded a $256,000 Project Grant from the National Science Foundation to develop a rapid, single-use, point-of-care lateral flow device for detecting kennel cough pathogens. The one-year award, made under the NSF Technology, Innovation, and Partnerships program, will support test validation, prototype manufacturing, and clinical evaluation to demonstrate the feasibility of detecting multiple bacteria and viruses associated with kennel cough in a single diagnostic test....

VERY RAPID, LOW COST MULTIPLEXED TEST FOR SARS, INFLUENZA A AND INFLUENZA B RESUBMISSION - PROJECT SUMMARY THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP A POINT-OF-CONTACT MOLECULAR DIAGNOSTIC TECHNOLOGY (TEST) FOR MULTI- PLEXED DETECTION OF A CORONAVIRUS (SARS-COV-2) AND INFLUENZA VIRUS. WHILE A POINT-OF-CARE DIAGNOSTIC MIGHT BE PERFORMED IN A PERIOD OF 10-20 MINUTES IN A CLINICAL SETTING, WE ENVISION A POINT-OF-CONTACT TEST BEING PERFORMED ABOUT 10 TIMES FASTER AND BEFORE SOMEONE PASSES THROUGH A DOOR, CHECKPOINT, AIRPORT GATE, OR BORDER. WE HAVE IDENTIFIED A STRATEGY FOR PERFORMING PCR THAT USES A NEW FORMAT TO SPEED THERMAL CYCLING WHILE ACHIEVING AP- PROXIMATELY 1,000,000-FOLD SAMPLE PARTITIONING TO ACCELERATE SAMPLE PREPARATION, WITHOUT MICRO-PATTERNING OR MICROFLUIDICS. AS DESCRIBED BELOW, WE HAVE ALREADY ESTABLISHED CRITICAL STRATEGIES FOR THE PROJECT INCLUDING (1) RAPID, UNIFORM CYCLING USING OPTICAL HEATING; (2) LARGE SCALE SAMPLE PARTITIONING; AND (3) A ONE-STEP LYSIS/RT- PCR ASSAY FOR ENVELOPED VIRUSES, INCLUDING SARS-COV-2 (THE VIRUS RESPONSIBLE FOR COVID-19). THIS PROJECT WILL PROVIDE THE BASIS FOR A MULTIPLEXED POINT-OF-CONTACT DIAGNOSTIC THAT CAN BE PERFORMED IN AS LITTLE AS 2 MINUTES AND AT A COST AS LOW AS $2/TEST FOR BILL OF MATERIAL (BOM) CONSUMABLES. WHEN AVAILABLE, THIS DIAGNOSTIC PLATFORM COULD BE USED ROUTINELY FOR DETECTING HIDDEN SPREADERS OF DISEASE AT, E.G., AIRPORTS, EN- TRANCES TO HOSPITALS, OR AT LONG-TERM CARE FACILITIES. AVAILABILITY OF THE DIAGNOSTIC WOULD BE TRANSFORMATIVE. BE- CAUSE OF ITS SPEED AND LOW COST, THE PLATFORM COULD PROVIDE THE FIRST POINT-OF-CONTACT MOLECULAR DIAGNOSTIC FOR DISEASES SUCH AS COVID-19, WHICH COULD DETECT ASYMPTOMATIC SPREADERS, E.G., AS THEY EMBARK OR DISEMBARK AT AIRPORTS. RAPID DEPLOYMENT OF THE TEST AT BORDERS OR ENTRY POINTS COULD PREVENT DISEASE FROM SPREADING BE- YOND AN INITIAL OUTBREAK. SIMILARLY, THE TEST COULD BE USED TO SCREEN EMPLOYEES WHEN THEY ARRIVE TO WORK AT HEALTH CARE FACILITIES TO PROTECT PATIENTS AND ESSENTIAL WORKERS. FINALLY, THE TEST COULD BE USED FOR ROUTINE SCREENING AT LARGE FACILITIES SUCH AS FACTORIES, FOOD PROCESSING OR DISTRIBUTION FACILITIES, AND LARGE GOVERNMENT BUILDINGS, REDUCING THE ECONOMIC IMPACT OF A ADDRESSING A VIRAL PANDEMIC SUCH AS COVID-19.

Posted 4/12/22